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Hypertension is the most common reversible risk factor for stroke, myocardial infarction, and heart failure, affecting greater than 60 million individuals in the United State alone and 1 billion globally 1 . According to the World Health Organization, hypertension is now the leading cause of preventable death worldwide 2 . Importantly, the prevalence and complications of hypertension increase significantly with age. However, despite the availability of many antihypertensive agents of distinct pharmacologic classes and evidence-based guideline recommendations for step-wise, multi-drug regimens, control of hypertension remains suboptimal with target blood pressure achieved in less than 50% of patients 1 . Although patient non-compliance and sub-maximal dosing of anti-hypertensive agents contribute to lack of blood pressure control, there is an unmet need for new approaches for treatment of hypertension. In this issue of Circulation, Boe and coworkers 3 report that pharmacological inhibition of plasminogen activator inhibitor-1 (PAI-1) is protective against the development of hypertension, cardiac hypertrophy, and periaortic fibrosis (i.e., arteriosclerosis) in mice treated with N -nitro-L-arginine methyl ester (L-NAME) to inhibit endothelial nitric oxide synthase (eNOS).
Since the molecular basis for primary or essential hypertension is unknown, the treatment of hypertension, excluding secondary or identifiable hypertension with known causes (e.g., chronic renal disease, renovascular, hyperaldosteronism, Cushing syndrome, pheochromocytoma), has been based largely upon targeting the underlying physiologic determinants of blood pressure-namely, intravascular volume (e.g., diuretics), neurohormonal drive (e.g., centrally-acting agents, renin angiotensin system blockade), systemic vascular resistance (e.g., vasodilators), and cardiac inotropy and chronotropy (e.g., beta-blockers) ( Figure   1 ). Another hallmark of hypertension is vascular remodeling of both small (inward eutrophic remodeling that decreases lumen area and increases systemic vascular resistance) and large pressure control, there is an unmet need for new approaches for treatment of hyp pe er e te te ten ns nsio io ion n. n. In I In his issue of Circulation, Boe and coworkers 3 report that pharmacological inhibition of pl plas as asmi mi mino n ge ge en n n acti ti iva vato t r inhibitor-1 (PAI-1) is pro ote e tec ct tive ag gainst th he e de eve vel lo lopment of hyp y ertension, Sinc ce e e th th the e e mo mo mole le ecu cu ula la ar r r ba ba b si si is s fo fo for r r pr pr rim im imar ar ary y y or or or e ess ss sen en enti ial al al h h hyp yp yper er erte te t ns ns sio io ion n n is is is u u unk nkno no n wn wn w , , th th the treatmen n nt (hypertrophic remodeling that increases medial thickness, extracellular matrix accumulation, and artery stiffness) arteries 4 . Anti-hypertensive agents variably affect vascular remodeling, possibly accounting for differential effectiveness of specific agents in preventing cardiovascular events 1 . Arterial collagen accumulation results in age-related aortic stiffening characterized by increased pulse pressure, which is an independent predictor of heart attack and stroke 5 .
Therapeutic approaches specifically targeting structural remodeling represent an important new area in cardiovascular disease.
Boe and colleagues 3 investigated whether a novel, orally active PAI-1 antagonist (TM5441) has a protective effect against L-NAME-induced systemic hypertension, arteriosclerosis, and vascular senescence. Wild-type mice received either L-NAME alone or L-NAME and TM5441 for 8 weeks. TM5441 attenuated the development of hypertension and cardiac hypertrophy compared to animals that had received L-NAME alone. Additionally, TM5441-treated mice had a 34% reduction in periaortic fibrosis. Finally, the development of vascular senescence was investigated by measuring p16Ink4a expression and telomere length in aortic tissue. L-NAME increased p16Ink4a expression levels and decreased telomere length, both of which were prevented with TM5441 co-treatment. Importantly, the favorable blood pressure and remodeling effects of PAI-1 inhibition appear to extend to other models of hypertension. PAI-1 deficiency prevented angiotensin II-induced arteriosclerosis 6 , and in supplemental data in the present study, reduced blood pressure.
The precise mechanism(s) responsible for the blood pressure lowering effect of PAI-1 inhibition is uncertain. The fact that wild-type mice treated with TM5441 alone exhibited no change in blood pressure suggests that inhibition of PAI-1 likely does not affect vascular tone or volume, but rather has structural effects. A closer look at the plasminogen activator system arteriosclerosis, and vascular senescence. Wild-type mice received either L-NA AME ME ME a a alo lo one ne ne o o or r r L-L-NAME and TM5441 for 8 weeks. TM5441 attenuated the development of hypertension and ca ard rd rdia ia iac c hy ype pe per r rtro oph h phy y compared to animals that h had d ad r r received L-NA A AME ME a al lo lone. Additionally, y t TM TM M5 5441-treat ted ed m m mice e ha ha ad d a a 34 34 4% % re re red du duct cti ion in in per ria aorti ti ic c c fi fi ib b bro o osis is. F Final ally y y, th th he e e de deve velo lo opm pm me e ent t o of of va vasc c cul ul ular ar ar s s sen en enes esce ce cenc nc ce e e w wa was s s in in i ve e est st s ig ig igat at ated ed b b by y y me me meas as sur ur urin in ing g g p1 p1 p16I 6I 6Ink nk nk4a 4a 4a e exp xp xpre re ess ss ssi io ion n n an and d d te te telo lo lom me mere re re l len en engt gt gth h in in in aortic tissue. e. L-L-L-NA NA NAME ME ME i inc nc cre re reas a ed ed ed p p p16 1 1 In In Ink4 k4 k4a a a ex ex expr pr pres es ssi si ion on o l l le ev evel el els s an a and d de de decr cr crea ea ease se sed d d te te elo lo l me me mere re re length, provides potential insights into TM5441 action. Plasmin is the major protease of the fibrinolytic system 7 and plays an important role in cell migration and tissue remodeling 8 by virtue of the fact that it is capable of degrading extracellular matrix proteins directly (fibrin, fibronectin, thrombospondins, and laminins) or indirectly (collagen, elastin) via the activation of metalloproteases 9 . Plasmin is derived from plasminogen by the endogenous plasminogen activators, tissue-type plasminogen activator (t-PA) 10 and urokinase-type plasminogen activators (u-PAs) 11 ( Figure 1) . The generation of plasmin is regulated by a balance between the plasminogen activators, t-PA and u-PA, and their SERPIN family inhibitors, plasminogen activator inhibitor-1 (PAl-l) 12 and plasminogen activator inhibitor-2 (PAl-2) 13 . Two functionally distinct forms of PAl-l, termed active and latent, have been identified 14 . In plasma, most of the PAI-1 circulates in the active form 15 , which deactivates spontaneously with a halflife of 1-2 h 16 and is stabilized by vitronectin 17 . PAI-1 is the primary physiological inhibitor of plasminogen activation. Active PAI-1 acts as a suicide substrate for t-PA and u-PA and rapidly neutralizes these plasminogen activators by forming a covalent complex 18 . In plasma, PAI-1 has a critical role in regulating endogenous fibrinolytic activity and resistance to thrombolysis.
In vascular tissues, PAI-1 mediates the response to injury by inhibiting cellular migration 19 and matrix degradation 20 . Excess PAI-1 is known to exacerbate the development of fibrosis in a variety of animal models 21, 22 . The plasminogen activator system also regulates vascular cell growth and remodeling as a consequence of plasmin-dependent processing of various cytokines and chemokines, including transforming growth factor-, interleukin-1, basic fibroblast growth factor, tumor necrosis factor-, and monocyte chemotactic protein-1 23 . TM5441 treatment did not fully attenuate the increase in systolic blood pressure due to chronic eNOS inhibition, but almost completely prevented collagen deposition and periaortic fibrosis. Thus, PAI-1 likely functionally distinct forms of PAl-l, termed active and latent, have been identified ed d 14 14 1 . In In In p p pla la lasm s sma, a, most of the PAI-1 circulates in the active form 15 , which deactivates spontaneously with a halfi ife fe e o o of f f 1 1-2 2 h h h 16 16 a and nd d i is stabilized by vitronectin 17 7 . P PA AI-1 is the pr p im im imar ry y ph physiologi g cal inhibitor of pl l p as s sm minogen act ti iv va ati tio on n. A Act ct tiv iv ve e PA PA AI I-I-1 1 a a acts a as s a su u ui ic cid de e e su su ub b bst tr trat te e e f f for t-t-PA PA A a a and nd d u u-P -P PA A A an an nd d ra rap pi id dl ly ne neut ut utra ra rali li lize ze zes s s th th thes es se e e pl pl plas as asm mi mino no nogen n n ac ac acti ti tiv va vato tors rs rs b b by y y fo fo form rm rmin ing g g a a co co cova va vale le lent nt n c c com om ompl pl plex ex ex 18 18 . I I In n n pl pl plas as asma ma a, , , PA PA PAI I-I-1 1 has a critical al l r r rol ol ole e e in in in r r reg eg e u ul u at at atin in ing g en en ndo do doge geno no nous u us f f fib ib ibri ri rino no n ly ly lyti ti t c c a ac acti ti tivi vi vity ty ty a and nd d r r re es esis is ista ta tan nc nce e to to t t thr hr hrom o ombolysis.
blocks proteolytic pathways that are critical to the maintenance of high blood pressure state as well as hypertension-associated arteriosclerosis.
This study challenges the present paradigm of anti-hypertensive treatments that focus on intravascular volume, neurohormonal drive, systemic vascular resistance, and cardiac inotropy and chronotropy rather than vascular structure and distensibility. Understanding the broader functions of PAI-1 in distinct cellular compartments and environments in vascular homeostasis and disease will be required to determine the clinical significance of these findings. The contribution by Boe et al. 3 in this issue of Circulation highlights the emergence and potential importance of vascular remodeling in animal models of hypertension (chronic positively related to measures of conduit artery stiffness (i.e., mean arterial pressu u sure e e, ce ce cent nt ntra ra ral l l pulse pressure, and forward pressure wave amplitude) even after multivariable adjustment 24 .
Se Sec co cond nd nd, is s s s sel el lec cti ti tive ve inhibition of PAI-1 achievabl l ble in vivo in huma ma m ns s? ? I I If f so, what is the most ap p pp pr rop o riate timi ming ng ng of f PA PA AI I-1 1 in in nhi hibi bi iti ti tion n---nam m me e ely, to to pre re ev ve ven nt nt h h hyp per ert tensi i ion n n in in n p p pre re-h h hyp yp yper ert t ten n nsiv ive n ndi di ivi vi vidu du dual al als s s or or i in n n pa pa pati ti tie en ents ts s w with h h es e ta ta tab bl blis ish he hed d d hy hy hype pe pert rt rte en ensi si sion on n? ? ? T T Thi hi h rd rd rd, is is i i i it t t po po poss ss sib ib i le le e f f for or or i i inh n nhib ib bit itio io on n n o of of PAI-1 to rev v ver er erse se se a a art rt rter er erio io iosc scle le ero ro rosi is s an an a d d d pe pe eri ri riao ao aort rt rtic ic ic f f fib ib ibro ro rosi si s s, , t t the he h re re reby by by, , fo o or r r ex ex exam am ampl pl ple, e, l l low ow wer er erin in ing pulse inhibition of eNOS or angiotensin II infusion) that may guide the study of human disease. The involvement of the plasminogen activator system in vascular homeostasis/remodeling and blood pressure, especially in the elderly, has profound implications for our patients. Novel therapeutic approaches available to reduce the increase in pulse pressure and arterial stiffness with age have been proposed previously 25 . These approaches involve converting enzyme inhibitors, nitrate derivatives, agents acting on collagen cross-linking, spironolactone and vasopeptidase inhibitors.
This study suggests a new approach involving structural remodeling of large and small arteries to prevent arteriosclerosis in hypertension. Understanding how to safely and efficiently translate these experimental observations might lead to new clinical applications, perhaps targeting PAI-1.
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